Table 1

		Enzymatic inhibition (IC₅₀, µM)		Cell growth inhibition (IC₅₀, µM)
	R	EGFR^b	VEGFR-2^c	PC3^a	HT29^a	MCF7^a
PD153035	3-Br	0.0005	0.42	>10	>10	>10
1	3-Br,4-CH₃	0.56	>10	>10	>10	>10
2	3-Cl,4-F	0.40	5.30	6.6 ±1.70	6.7 ±0.78	4.9 ±0.54
3	4-NHCOOCH₃	6.90	5.80	>10	>10	>10
4	3-CH₃,4-NHCOOC₂H₅	0.90	0.65	>10	>10	>10
5	3-Cl,4-NHCOOC₂H₅	1.00	0.50	9.8 ±0.35	>10	>10

^a The cell growth rate was evaluated by performing the MTS assay. Data are represented as the mean ± SEM of at three experiments performed in triplicate. Higher concentrations were not used to avoid precipitation of the compound in the culture medium
^bInhibition of EGFR (purified from human carcinoma A431 cells) tyrosine kinase activity
^cInhibition of VEGFR-2 (recombinant protein) tyrosine kinase activity

Table 1: Enzymatic and cell growth inhibition results of quinazoline derivatives.